July 13, 2016 - Expert key opinion leader Dr. Deborah A. Lannigan from Vanderbilt University recently published "that targeting the downstream effectors of MEK1/2, like RSK, are an untapped source of drug targets and that they will generate less side effects than MEK1/2 inhibitors because they regulated fewer effectors". She went on to mention that "based on overwhelming evidence that RSK is involved in a number of diseases that have high moralities it seems surprising that there are no RSK modulators that have pharmacokinetic properties suitable for in vivo use". Read the abstract here
Forbes - August 1, 2016 - "Biotech has been one of the hottest sectors in the venture capital asset class over the past new years. Strong IPO and M&A markets have put wind in the sails of the space since 2012, and robust investment activity has enabled a wave of well-funded biotechs to mature with a lower cost of capital than a decade ago."
January 6, 2016 - Many factors contribute to the rapid forecasted growth of the breast cancer treatment market over the next seven years. Along with epidemiological factors, the impact of therapeutic regimens involving multiple combination therapies will help drive growth.
May 27, 2015 - The latest annual report from the Canadian Cancer Society predicts that the number of cancer cases will rise by 40% in the next 15 years due to an aging and increasing population.